Assessment of Post-COVID-19 Complications in the Pakistani Population: A Detailed Survey into Late-Onset Adverse Events through Cross-Sectional Analysis
Post-COVID-19 Complications in the Pakistani Population: Late-Onset Adverse Events
DOI:
https://doi.org/10.54393/pbmj.v8i8.1299Keywords:
Covid-19 Pandemic, Vaccination, Adverse Effects, ImmunityAbstract
COVID-19 was a health crisis that severely obstructed the healthcare system and public well-being. Although vaccination has been very instrumental in reducing mortality and morbidity due to COVID-19, concerns are still prevalent regarding its short- and long-term side effects. Objectives: To investigate the incidence and severity of the pandemic, which vary considerably across different demographic groups, especially in older age. Methods: The current descriptive exploratory study examines post-vaccination effects among various age and gender groups in Pakistan through an online survey of 220 individuals. Results: Nearly 24% of respondents have suffered from COVID-19 during the pandemic, with a high prevalence in older age. A vast majority, i.e., 92% were vaccinated for COVID-19. Results show that 47 percent of respondents have been affected by one or more kinds of post-vaccination effects. Segregating results, 28 percent faced neurological effects, 16% cardiovascular effects, 11% bleeding complications, 11% gastrointestinal effects, and 18% allergic reactions. Among female, 22% reported menstrual changes after receiving the vaccination for COVID-19. Two deaths were also reported among the respondents temporally following vaccination; however, the small number and the study design preclude any causal inference with multiple post-vaccination effects. Conclusions: Pre-existing health conditions, experiencing surgery, and growing age were significantly associated with a higher likelihood of reporting post-vaccination complications. This study plays an important part in tailoring future vaccination approaches and plans, eventually assisting Pakistan’s long-term public health preparedness.
References
World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard [Internet]. Geneva: World Health Organization; 2024 [cited 2024 Jan 25]. Available from: https://covid19.who.int.
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N et al. Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis. The Lancet Infectious Diseases. 2020 Jun; 20(6): 669-77. doi: 10.1016/S1473-3099(20)30243-7. DOI: https://doi.org/10.1016/S1473-3099(20)30243-7
Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR et al. Male Sex Identified by Global COVID-19 Meta-Analysis as A Risk Factor for Death and ITU Admission. Nature Communications. 2020 Dec; 11(1): 6317. doi: 10.1038/s41467-020-19741-6. DOI: https://doi.org/10.1038/s41467-020-19741-6
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. New England Journal of Medicine. 2020 Dec; 383(27): 2603-15. doi: 10.1056/NEJMoa2034577. DOI: https://doi.org/10.1056/NEJMoa2034577
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021 Feb; 384(5): 403-16. doi: 10.1056/NEJMoa2035389. DOI: https://doi.org/10.1056/NEJMoa2035389
Gee J. First Month of COVID-19 vaccine Safety Monitoring—United States, December 14, 2020–January 13, 2021. Morbidity and Mortality Weekly Report. 2021; 70(8): 283–288. doi: 10.15585/mmwr.mm7008e3. DOI: https://doi.org/10.15585/mmwr.mm7008e3
Frydrysiak-Brzozowska A, Haor B, Pluta A, Głowacka M. Population-Based Analysis of Vaccination Status and Post-Vaccination Adverse Events in Adults Aged 55 and Older. Journal of Clinical Medicine. 2025 Jun; 14(12): 4297. doi: 10.3390/jcm14124297. DOI: https://doi.org/10.3390/jcm14124297
Link-Gelles R. Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness among Adults Aged ≥ 18 years—VISION and IVY Networks, September 2024–January 2025. Morbidity and Mortality Weekly Report. 2025; 74.
Chen CY and Su TC. Benefits and Harms of Covid-19 Vaccines in Cardiovascular Disease: A Comprehensive Review. Journal of Lipid and Atherosclerosis. 2023 May; 12(2): 119. doi: 10.12997/jla.2023.12.2.119. DOI: https://doi.org/10.12997/jla.2023.12.2.119
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al. Factors Associated with Hospitalization and Critical Illness Among 4,103 Patients with COVID-19 Disease in New York City. MedRxiv. 2020 Apr: 2020-04. doi: 10.1101/2020.04.08.20057794. DOI: https://doi.org/10.1101/2020.04.08.20057794
Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S et al. Neurological Complications After First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection. Nature Medicine. 2021 Dec; 27(12): 2144-53. doi: 10.1038/s41591-021-01556-7. DOI: https://doi.org/10.1038/s41591-021-01556-7
Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. Journal of the American Medical Association. 2021 Apr; 325(15): 1562-5. doi: 10.1001/jama.2021.3976. DOI: https://doi.org/10.1001/jama.2021.3976
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P et al. Vaccine Side-Effects and SARS-CoV-2 Infection After Vaccination in Users of the COVID Symptom Study App in the UK: A Prospective Observational Study. The Lancet Infectious Diseases. 2021 Jul; 21(7): 939-49. doi: 10.1016/S1473-3099(21)00224-3. DOI: https://doi.org/10.1016/S1473-3099(21)00224-3
Male V. Menstrual Changes After Covid-19 Vaccination. British Medical Journal. 2021 Sep; 374. doi: 10.1136/bmj.n2211. DOI: https://doi.org/10.1136/bmj.n2211
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS et al. Post-Acute COVID-19 Syndrome. Nature Medicine. 2021 Apr; 27(4): 601-15. doi: 10.1038/s41591-021-01283-z. DOI: https://doi.org/10.1038/s41591-021-01283-z
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022 Mar; 185(5): 881-95.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Journal of the American Medical Association. 2021 Oct; 326(14): 1390-9. doi: 10.1001/jama.2021.15072. DOI: https://doi.org/10.1001/jama.2021.15072
Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R et al. Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting. New England Journal of Medicine. 2021 Sep; 385(12): 1078-90. doi: 10.1056/NEJMoa2110475. DOI: https://doi.org/10.1056/NEJMoa2110475
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine. 2021 Jun; 384(22): 2092-101. doi: 10.1056/NEJMoa2104840. DOI: https://doi.org/10.1056/NEJMoa2104840
Loo J, Spittle DA, Newnham M. COVID-19, Immunothrombosis and Venous Thromboembolism: Biological Mechanisms. Thorax. 2021 Apr; 76(4): 412-20. doi: 10.1136/thoraxjnl-2020-216243. DOI: https://doi.org/10.1136/thoraxjnl-2020-216243
World Health Organization. COVID-19 Vaccines: Safety Surveillance Manual. World Health Organization. 2020 Dec.
Edelman A, Boniface ER, Male V, Cameron ST, Benhar E, Han L et al. Association Between Menstrual Cycle Length And Covid-19 Vaccination: Global, Retrospective Cohort Study Of Prospectively Collected Data. British Medical Journal Medicine. 2022 Sep; 1(1): e000297. doi: 10.1136/bmjmed-2022-000297. DOI: https://doi.org/10.1136/bmjmed-2022-000297
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan BioMedical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments editor@pakistanbmj.com
